Linking Molecular Diagnostics to Molecular Therapeutics: Targeting the PI3K Pathway in Breast Cancer

Gordon Mills, Elise Kohn, Yiling Lu, Astrid Eder, Xianjun Fang, Hongwei Wang, Robert C. Bast, Joe Gray, Robert Jaffe, Gabriel Hortobagyi

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Modulation of the signaling pathways that are aberrant in cancer cells has the potential to provide an effective nontoxic approach to patient management in a broad range of cancers. This quest has taken a major leap forward with the demonstration that STI-571 (imatinib mesylate) induces clinical and molecular remissions in the majority of patients with interferon-refractory chronic myelogenous leukemia and gastrointestinal stromal tumors through inhibition of the Bcr/Abl fusion protein required for the initiation and progression of chronic myelogenous leukemia and inhibition of a mutant, activated c-kit present in gastrointestinal stromal tumors. Support for the concept of targeting products of fusion genes found in specific cancers was first provided by the efficacy of all-trans retinoic acid in acute promyelocytic leukemia where the RARα all-trans retinoic acid target is the target of multiple different chromosomal rearrangements. In breast cancer, trastuzumab, which alters the function of the HER2 protooncogene overexpressed in a portion of breast cancers, provides an additional example of targeting specific molecular aberrations present in cancer cells. Although the target for these signal transduction modulators is functional in normal cells, acceptable therapeutic indices sufficient to prevent tumor growth without unacceptable toxicities have been observed. Whether STI-571 and other signal transduction modulators also target the stroma, and specifically the neovasculature, in addition to the tumor remains an open question. The presence of the target in the cancer cells or in the surrounding stroma appears to be required but not sufficient for the action of molecular therapeutics. Thus, linking molecular diagnostics to identify patients where the target is amplified or activated and driving the pathophysiology of the patients' tumor to effective molecular therapeutics will be necessary to translate these concepts into approaches that will alter the outcome for breast cancer patients. This review will focus on the phosphatidylinositol 3-kinase pathway and novel molecules targeting this pathway to illustrate the questions and challenges underlying the implementation of molecular therapeutics in breast cancer.

Original languageEnglish (US)
Pages (from-to)93-104
Number of pages12
JournalSeminars in Oncology
Volume30
Issue number5 SUPPL. 16
StatePublished - Oct 2003
Externally publishedYes

Fingerprint

Molecular Pathology
Phosphatidylinositol 3-Kinases
Breast Neoplasms
Neoplasms
Gastrointestinal Stromal Tumors
Therapeutics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tretinoin
Signal Transduction
bcr-abl Fusion Proteins
Phosphatidylinositol 3-Kinase
Acute Promyelocytic Leukemia
Gene Fusion
Interferons
Growth

ASJC Scopus subject areas

  • Oncology

Cite this

Mills, G., Kohn, E., Lu, Y., Eder, A., Fang, X., Wang, H., ... Hortobagyi, G. (2003). Linking Molecular Diagnostics to Molecular Therapeutics: Targeting the PI3K Pathway in Breast Cancer. Seminars in Oncology, 30(5 SUPPL. 16), 93-104.

Linking Molecular Diagnostics to Molecular Therapeutics : Targeting the PI3K Pathway in Breast Cancer. / Mills, Gordon; Kohn, Elise; Lu, Yiling; Eder, Astrid; Fang, Xianjun; Wang, Hongwei; Bast, Robert C.; Gray, Joe; Jaffe, Robert; Hortobagyi, Gabriel.

In: Seminars in Oncology, Vol. 30, No. 5 SUPPL. 16, 10.2003, p. 93-104.

Research output: Contribution to journalArticle

Mills, G, Kohn, E, Lu, Y, Eder, A, Fang, X, Wang, H, Bast, RC, Gray, J, Jaffe, R & Hortobagyi, G 2003, 'Linking Molecular Diagnostics to Molecular Therapeutics: Targeting the PI3K Pathway in Breast Cancer', Seminars in Oncology, vol. 30, no. 5 SUPPL. 16, pp. 93-104.
Mills, Gordon ; Kohn, Elise ; Lu, Yiling ; Eder, Astrid ; Fang, Xianjun ; Wang, Hongwei ; Bast, Robert C. ; Gray, Joe ; Jaffe, Robert ; Hortobagyi, Gabriel. / Linking Molecular Diagnostics to Molecular Therapeutics : Targeting the PI3K Pathway in Breast Cancer. In: Seminars in Oncology. 2003 ; Vol. 30, No. 5 SUPPL. 16. pp. 93-104.
@article{b426ea7c98be4961b44fcbc1c657a31a,
title = "Linking Molecular Diagnostics to Molecular Therapeutics: Targeting the PI3K Pathway in Breast Cancer",
abstract = "Modulation of the signaling pathways that are aberrant in cancer cells has the potential to provide an effective nontoxic approach to patient management in a broad range of cancers. This quest has taken a major leap forward with the demonstration that STI-571 (imatinib mesylate) induces clinical and molecular remissions in the majority of patients with interferon-refractory chronic myelogenous leukemia and gastrointestinal stromal tumors through inhibition of the Bcr/Abl fusion protein required for the initiation and progression of chronic myelogenous leukemia and inhibition of a mutant, activated c-kit present in gastrointestinal stromal tumors. Support for the concept of targeting products of fusion genes found in specific cancers was first provided by the efficacy of all-trans retinoic acid in acute promyelocytic leukemia where the RARα all-trans retinoic acid target is the target of multiple different chromosomal rearrangements. In breast cancer, trastuzumab, which alters the function of the HER2 protooncogene overexpressed in a portion of breast cancers, provides an additional example of targeting specific molecular aberrations present in cancer cells. Although the target for these signal transduction modulators is functional in normal cells, acceptable therapeutic indices sufficient to prevent tumor growth without unacceptable toxicities have been observed. Whether STI-571 and other signal transduction modulators also target the stroma, and specifically the neovasculature, in addition to the tumor remains an open question. The presence of the target in the cancer cells or in the surrounding stroma appears to be required but not sufficient for the action of molecular therapeutics. Thus, linking molecular diagnostics to identify patients where the target is amplified or activated and driving the pathophysiology of the patients' tumor to effective molecular therapeutics will be necessary to translate these concepts into approaches that will alter the outcome for breast cancer patients. This review will focus on the phosphatidylinositol 3-kinase pathway and novel molecules targeting this pathway to illustrate the questions and challenges underlying the implementation of molecular therapeutics in breast cancer.",
author = "Gordon Mills and Elise Kohn and Yiling Lu and Astrid Eder and Xianjun Fang and Hongwei Wang and Bast, {Robert C.} and Joe Gray and Robert Jaffe and Gabriel Hortobagyi",
year = "2003",
month = "10",
language = "English (US)",
volume = "30",
pages = "93--104",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5 SUPPL. 16",

}

TY - JOUR

T1 - Linking Molecular Diagnostics to Molecular Therapeutics

T2 - Targeting the PI3K Pathway in Breast Cancer

AU - Mills, Gordon

AU - Kohn, Elise

AU - Lu, Yiling

AU - Eder, Astrid

AU - Fang, Xianjun

AU - Wang, Hongwei

AU - Bast, Robert C.

AU - Gray, Joe

AU - Jaffe, Robert

AU - Hortobagyi, Gabriel

PY - 2003/10

Y1 - 2003/10

N2 - Modulation of the signaling pathways that are aberrant in cancer cells has the potential to provide an effective nontoxic approach to patient management in a broad range of cancers. This quest has taken a major leap forward with the demonstration that STI-571 (imatinib mesylate) induces clinical and molecular remissions in the majority of patients with interferon-refractory chronic myelogenous leukemia and gastrointestinal stromal tumors through inhibition of the Bcr/Abl fusion protein required for the initiation and progression of chronic myelogenous leukemia and inhibition of a mutant, activated c-kit present in gastrointestinal stromal tumors. Support for the concept of targeting products of fusion genes found in specific cancers was first provided by the efficacy of all-trans retinoic acid in acute promyelocytic leukemia where the RARα all-trans retinoic acid target is the target of multiple different chromosomal rearrangements. In breast cancer, trastuzumab, which alters the function of the HER2 protooncogene overexpressed in a portion of breast cancers, provides an additional example of targeting specific molecular aberrations present in cancer cells. Although the target for these signal transduction modulators is functional in normal cells, acceptable therapeutic indices sufficient to prevent tumor growth without unacceptable toxicities have been observed. Whether STI-571 and other signal transduction modulators also target the stroma, and specifically the neovasculature, in addition to the tumor remains an open question. The presence of the target in the cancer cells or in the surrounding stroma appears to be required but not sufficient for the action of molecular therapeutics. Thus, linking molecular diagnostics to identify patients where the target is amplified or activated and driving the pathophysiology of the patients' tumor to effective molecular therapeutics will be necessary to translate these concepts into approaches that will alter the outcome for breast cancer patients. This review will focus on the phosphatidylinositol 3-kinase pathway and novel molecules targeting this pathway to illustrate the questions and challenges underlying the implementation of molecular therapeutics in breast cancer.

AB - Modulation of the signaling pathways that are aberrant in cancer cells has the potential to provide an effective nontoxic approach to patient management in a broad range of cancers. This quest has taken a major leap forward with the demonstration that STI-571 (imatinib mesylate) induces clinical and molecular remissions in the majority of patients with interferon-refractory chronic myelogenous leukemia and gastrointestinal stromal tumors through inhibition of the Bcr/Abl fusion protein required for the initiation and progression of chronic myelogenous leukemia and inhibition of a mutant, activated c-kit present in gastrointestinal stromal tumors. Support for the concept of targeting products of fusion genes found in specific cancers was first provided by the efficacy of all-trans retinoic acid in acute promyelocytic leukemia where the RARα all-trans retinoic acid target is the target of multiple different chromosomal rearrangements. In breast cancer, trastuzumab, which alters the function of the HER2 protooncogene overexpressed in a portion of breast cancers, provides an additional example of targeting specific molecular aberrations present in cancer cells. Although the target for these signal transduction modulators is functional in normal cells, acceptable therapeutic indices sufficient to prevent tumor growth without unacceptable toxicities have been observed. Whether STI-571 and other signal transduction modulators also target the stroma, and specifically the neovasculature, in addition to the tumor remains an open question. The presence of the target in the cancer cells or in the surrounding stroma appears to be required but not sufficient for the action of molecular therapeutics. Thus, linking molecular diagnostics to identify patients where the target is amplified or activated and driving the pathophysiology of the patients' tumor to effective molecular therapeutics will be necessary to translate these concepts into approaches that will alter the outcome for breast cancer patients. This review will focus on the phosphatidylinositol 3-kinase pathway and novel molecules targeting this pathway to illustrate the questions and challenges underlying the implementation of molecular therapeutics in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=10744230387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744230387&partnerID=8YFLogxK

M3 - Article

C2 - 14613030

AN - SCOPUS:10744230387

VL - 30

SP - 93

EP - 104

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5 SUPPL. 16

ER -